MSN

Yeah, the setup here is fascinating just because of how direct it is.

So the patents claim a genus of crystalline cabozandinib l-mallet salts and MSN, the generic challenger, They looked at the claims and actually conceded infringement.

They just admitted it.

Yeah.

The generics argument essentially boils down to, well, you claimed an entire category of crystalline salts, but you didn't actually describe enough of them in your specification to prove to the public that you possessed the entire genus.

Right.

And looking at the facts, I can completely see why MSN pushed this.

If an inventor claims an entire genus of crystalline salts, but the specification only explicitly identifies two specific polymorphs, they called them N1 and N2, how on earth does that satisfy the Ariad test?

That changes your leverage in the next supply negotiation, not the one after it.

On the regulatory side, SK Biopharmaceuticals settled its patent fight with MSN Laboratories over cenobamate.

Xcopri in the US Delaware litigation dismissed.

MSN gets rights to launch a generic in the future subject to patent protection and agreed conditions.

Terms, confidential.

The structural point is what the dispute was actually about.

Settled isn't dated.

That's the discipline I'd apply.